Verona Pharma (VRNA)
NASDAQ: VRNA
· Real-Time Price · USD
91.90
-0.30 (-0.33%)
At close: Jun 16, 2025, 2:26 PM
-0.33% (1D)
Bid | 91.75 |
Market Cap | 7.81B |
Revenue (ttm) | 118.53M |
Net Income (ttm) | -164.02M |
EPS (ttm) | -2 |
PE Ratio (ttm) | -45.95 |
Forward PE | 106.34 |
Analyst | Strong Buy |
Ask | 91.9 |
Volume | 630,965 |
Avg. Volume (20D) | 1,523,164.6 |
Open | 93.52 |
Previous Close | 92.20 |
Day's Range | 91.15 - 94.25 |
52-Week Range | 14.14 - 94.45 |
Beta | 0.22 |
About VRNA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol VRNA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for VRNA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts5 days ago
+3.77%
Verona Pharma shares are trading higher after Jeff...
Unlock content with
Pro Subscription
1 month ago
+6.38%
Verona Pharma shares are trading higher after the company reported better-than-expected Q1 revenue results.

1 month ago · seekingalpha.com
Silencing The Doubters: Verona Pharma Could Be Sitting On A BlockbusterVRNA's COPD drug Ohtuvayre shows impressive Q1'25 net sales of $71.3M in just its third quarter of sales, all but confirming the blockbuster future of the drug. Ongoing R&D and trials, including a pha...

2 months ago · seekingalpha.com
Verona Pharma's Bull Case Holds, But Lifecycle Extension Is CriticalOhtuvayre's robust launch for COPD treatment exceeded expectations, with Q4 revenue of $36.6 million and FY24 revenue of $42.3 million, indicating strong market demand. Verona's financial health is so...